Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
This NIH (R01) opportunity funds basic research into the harmful effects of acute exposure to ultra-potent synthetic opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations, includi…
- Deadline
- Nov 18, 2027
- Posted
- Nov 20, 2024
- Award amount
- Up to $300,000
Don’t miss this deadline
We’ll email you before Nov 18, 2027 so you have time to apply.
In plain English
This NIH (R01) opportunity funds basic research into the harmful effects of acute exposure to ultra-potent synthetic opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations, including delayed effects. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $300,000.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
About this grant
This notice of funding opportunity (NOFO) will support research towards understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations (fentanyl and xylazine). This NOFO will also support research on the persistent and/or delayed pathophysiological effects after acute exposure to such agents.
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Education and Health — soonest deadline first.
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 8 days
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
National Institutes of Health · Up to $250K · Due in 8 days
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 8 days
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 8 days
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
National Institutes of Health · Amount varies · Due in 8 days
NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
National Institutes of Health · Up to $750K · Due Nov 13, 2026
Also listed under National Institutes of Health, Education Grants and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.